A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
Information source: Indiana University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asperger's Disorder; Pervasive Developmental Disorder
Intervention: aripiprazole (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Indiana University School of Medicine Official(s) and/or principal investigator(s): Kimberly A. Stigler, MD, Principal Investigator, Affiliation: Indiana University School of Medicine
Summary
The purpose of this study is to develop a better tolerated and more effective pharmacologic
treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder.
This is an open-label investigation of aripiprazole in the management of the maladaptive
behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for
reducing aggression and repetitive behavior.
Clinical Details
Official title: An Open-Label Study of Aripiprazole in Children and Adolescents With Autistic Disorder
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The Clinical Global Impression(CGI)Improvement Scale.The Irritability subscale of the Aberrant Behavior Checklist (ABC)
Secondary outcome: The Clinical Global Impression Severity Scale.The Compulsion subscale of the Children's Yale-Brown Obsessive-Compulsive(CY-BOCS). The Vineland Maladaptive Behavior Subscale.
Detailed description:
Pervasive developmental disorders (PDD) are characterized be severe impairments in social
interaction and communication in addition to restricted patterns of interests and
activities. Research suggests that a dysregulation of the dopamine and serotonin systems
contributes to these interfering behaviors in individuals with PDD. After benefits of
typical neuroleptics were reported in subjects with PDD's, research shifted to the atypical
antipsychotics, which have been shown to be better tolerated and effective in this
population. However, the atypical antipsychotics have also been associated with adverse
effects. Thus there remains a need for a novel pharmacotherapy that would be safe and
effective for children and adolescents with PDD's including Asperger's disorder and PDD Not
Otherwise Specified (PDD NOS). We hypothesize that aripiprazole will be effective for
reducing aggression and repetitive behavior. We also hypothesize that aripiprazole will be
well tolerated, with low risk for extrapyramidal symptoms, hyperprolactinemia, weight gain,
or corrected QT interval (QTc) prolongation. In addition, this open-label study will serve
to stimulate more definitive, controlled research.
Eligibility
Minimum age: 4 Years.
Maximum age: 17 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Mental age of 18 months
- Diagnosis of Asperger's Disorder or Pervasive Developmental Disorder
- Good health overall
- Free of all psychotropic medication for 2 weeks
Exclusion Criteria:
- Weight less than 15kg
- Subjects who have received an adequate trial of aripiprazole
- An active seizure disorder
- A significant medical condition
- History of neuroleptic malignant syndrome
- Females with positive Beta human chorionic gonadotropin(HCG) pregnancy test
Locations and Contacts
Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana 46020, United States
Additional Information
Starting date: January 2005
Last updated: June 3, 2014
|